Renal function in patients with chronic kidney disease and hypertension degree 1–2 against the background of SARS-CoV-2

Renal function in patients with chronic kidney disease and hypertension degree 1–2 against the background of SARS-CoV-2

Background. SARS-CoV-2 infection in patients with chronic kidney disease (CKD) and hypertension degree 1–2 worsens the state of the cardiovascular system and may contribute to cardiovascular events and adverse renal risks. The presence of CKD in combination with hypertension degree 1–2 and its medic...

Full description

Bibliographic Details
Main Author:	I.M. Zavalna
Format:	Article
Language:	English
Published:	Zaslavsky O.Yu. 2023-03-01
Series:	Počki
Subjects:	chronic kidney disease bircov trial angiotensin-converting enzyme inhibitors angiotensin receptor blockers direct renin inhibitors sars-cov-2 hypertension
Online Access:	https://kidneys.zaslavsky.com.ua/index.php/journal/article/view/390

Similar Items

Final results of BIRCOV trial (ARB, ACEI, DRi in COVID-19)
by: D.D. Ivanov, et al.
Published: (2021-09-01)

Hypertension, medications, and risk of severe COVID‐19: A Massachusetts community‐based observational study
by: Ann Z. Bauer, et al.
Published: (2021-01-01)

A high sodium intake reduces antiproteinuric response to renin–angiotensin–aldosterone system blockade in kidney transplant recipients
by: Elena Monfá, et al.
Published: (2016-09-01)

Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement
by: Fabrizio Buffolo, et al.
Published: (2021-05-01)

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
by: Juan Meng, et al.
Published: (2020-01-01)

Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension
by: Sonali R. Gnanenthiran, et al.
Published: (2022-09-01)

Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
by: Jenny I. Shen, et al.
Published: (2017-06-01)

Medicinal chemistry of the renin-angiotensin system /
by: Timmermans, P. B. M. W. M., et al.
Published: (1994)

Blood Pressure Control and Antihypertensive Treatment among Hemodialysis Patients—Retrospective Single Center Experience
by: Piotr Skonieczny, et al.
Published: (2021-06-01)

Angiotensins and rheumatoid arthritis
by: N. M. Savushkina, et al.
Published: (2019-01-01)

Effect of ACE inhibitors on the course of SARS-CoV-2 in a patient with pre-existing chronic kidney disease: a clinical case
by: I.M. Zavalna
Published: (2023-09-01)

Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
by: Rohan Khera, et al.
Published: (2021-07-01)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
by: Seok Hui Kang, et al.
Published: (2023-05-01)

A study of prognosis and outcome of COVID-19-infected hypertensive patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
by: M S Bharath, et al.
Published: (2024-01-01)

Impact of renin-angiotensin system inhibitors on the survival of patients with rectal cancer
by: Marcin Zeman, et al.
Published: (2022-07-01)

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study
by: Ju Hwan Kim, et al.
Published: (2020-12-01)

The problem of determining the efficiency of treatmentin the era of evidence-based medicine: international and domestic experience
by: S R Gilyarevsky
Published: (2014-06-01)

Angiotensin‐Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID‐19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System
by: Jaejin An, et al.
Published: (2021-02-01)

COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system
by: Jaejin An, et al.
Published: (2021-06-01)

Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients
by: Annina S. Vischer, et al.
Published: (2021-03-01)

Survival Benefit of Renin-Angiotensin System Blockers in Critically Ill Cancer Patients: A Retrospective Study
by: Driss Laghlam, et al.
Published: (2023-06-01)

Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study
by: Francisco J. de Abajo, et al.
Published: (2021-05-01)

The effectiveness of zofenopril in patients with cardiovascular disease
by: V G Kukes, et al.
Published: (2014-06-01)

Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis
by: Andrea Laurentius, et al.
Published: (2021-02-01)

From gene to protein - experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension
by: Sheila K Patel, et al.
Published: (2014-06-01)

Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
by: Jordan Loader, et al.
Published: (2022-06-01)

Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series
by: Mishita Goel, et al.
Published: (2020-08-01)

Long-term use of renin-angiotensin-system inhibitors after acute myocardial infarction is not associated with survival benefits: Analysis of data from the Korean acute myocardial infarction registry-national institutes of health registry
by: Chan Soon Park, et al.
Published: (2022-08-01)

Antecedent Administration of Angiotensin‐Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID‐19 Syndrome
by: Alberto Palazzuoli, et al.
Published: (2020-11-01)

Impact of Renin‐Angiotensin System Inhibitors on Long‐Term Clinical Outcomes of Patients With Coronary Artery Spasm
by: Byoung Geol Choi, et al.
Published: (2016-07-01)

Local Angiotensin-Converting Enzyme 2 Gene Expression in Kidney Allografts Is Not Affected by Renin-Angiotensin-Aldosterone Inhibitors
by: Monika Cahova, et al.
Published: (2021-03-01)

Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study
by: De Nicola Luca, et al.
Published: (2012-11-01)

Prospects of using genetic testing to increase the effectiveness of antihypertensive therapy
by: N. V. Drobotya, et al.
Published: (2020-06-01)

Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective
by: Hee-Sung Kim, et al.
Published: (2021-02-01)

New Users of Angiotensin II Receptor Blocker–Versus Angiotensin‐Converting Enzyme Inhibitor–Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD‐BP and SPRINT
by: Jordan B. King, et al.
Published: (2023-09-01)

Associations Between the Use of Renin–Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies
by: Xiao-Ce Dai, et al.
Published: (2021-04-01)

Effect of ACEi and ARBs vs Non ACEi/ARBs in Hypertension with Respect to Renal Outcomes in COVID-19 Infection: A Retrospective Cohort Study
by: S Ravitej, et al.
Published: (2022-11-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study
by: Jae Hyun Bae, et al.
Published: (2021-05-01)

Study Hypothesis: Age, Gender, Presence of Diabetes Mellitus or Hypertension, and Anti-Hypertensive Drugs Are Independent Risk Factors for COVID-19 Mortality
by: Faruk Karandere, et al.
Published: (2023-01-01)